EE35 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Vs. Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Non-Squamous, Advanced Non-Small Cell Lung Cancer in the USA
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.287
https://www.valueinhealthjournal.com/article/S1098-3015(22)00488-0/fulltext
Title :
EE35 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Vs. Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Non-Squamous, Advanced Non-Small Cell Lung Cancer in the USA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00488-0&doi=10.1016/j.jval.2022.04.287
First page :
Section Title :
Open access? :
No
Section Order :
10253